Evidera, , Bethesda, Maryland, USA.
Thorax. 2014 May;69(5):443-9. doi: 10.1136/thoraxjnl-2013-204428. Epub 2014 Mar 4.
Although respiratory symptoms are characteristic features of COPD, there is no standardised method for quantifying their severity in stable disease.
To evaluate the EXACT-Respiratory Symptom (E-RS) measure, a daily diary comprising 11 of the 14 items in the Exacerbations of Chronic Pulmonary Disease Tool (EXACT).
Qualitative: patient focus group and interviews to address content validity. Quantitative: secondary data analyses to test reliability and validity.
Qualitative: n=84; mean (SD) age 65 (10) years, FEV1 1.2(0.4) L; 44% male. Subject descriptions of their respiratory symptoms were consistent with E-RS content and structure. Quantitative: n=188; mean (SD) age 66 (10) years, FEV1 1.2(0.5) L; 50% male. Factor analysis (FA) showed 3 subscales: RS-Breathlessness, RS-Cough & Sputum, and RS-Chest Symptoms; second-order FA supported a general factor and total score. Reliability (total and subscales): 0.88, 0.86, 0.73, 0.81; 2-day test-retest ICC: 0.90, 0.86, 0.87, 0.82, respectively.
Total scores correlated significantly (p < 0.0001) with SGRQ Total (r=0.75), Symptoms (r=0.66), Activity (r=0.57), Impact (r=0.70) scores; subscale correlations were also significant (r=0.26, p < 0.05 (RS-Chest Symptoms with Activity) to r=0.69, p < 0.0001 (RS-Cough & Sputum with Symptoms). RS-Breathlessness correlated with rescue medication use (r=0.32, p < 0.0001), clinician-reported mMRC (r=0.33, p < 0.0001), and FEV1% predicted (r=-0.17, p < 0.05). E-RS scores differentiated groups based on chronic bronchitis diagnosis (p < 0.01-0.001), smoking status (p < 0.05-0.001), and rescue medication use (p < 0.05-0.0001).
Results suggest the RS-Total is a reliable and valid instrument for evaluating respiratory symptom severity in stable COPD. Further study of sensitivity to change is warranted.
尽管呼吸症状是 COPD 的特征性表现,但目前尚无用于量化稳定期疾病严重程度的标准化方法。
评估 EXACT-Respiratory Symptom(E-RS)量表,该量表是慢性肺部疾病加重工具(EXACT)的 14 个项目中的 11 个项目组成的日常日记。
定性:患者焦点小组和访谈以解决内容有效性。定量:二次数据分析以测试可靠性和有效性。
定性:n=84;平均(SD)年龄 65(10)岁,FEV1 1.2(0.4)L;44%为男性。患者对呼吸症状的描述与 E-RS 的内容和结构一致。定量:n=188;平均(SD)年龄 66(10)岁,FEV1 1.2(0.5)L;50%为男性。因子分析(FA)显示 3 个分量表:RS-呼吸困难、RS-咳嗽和咳痰、RS-胸部症状;二阶 FA 支持一个一般因子和总分。可靠性(总分和分量表):0.88、0.86、0.73、0.81;2 天测试-重测 ICC:0.90、0.86、0.87、0.82,分别。
总分与 SGRQ 总分(r=0.75)、症状(r=0.66)、活动(r=0.57)、影响(r=0.70)显著相关(p<0.0001);分量表相关性也显著(r=0.26,p<0.05(RS-胸部症状与活动)至 r=0.69,p<0.0001(RS-咳嗽和咳痰与症状)。RS-呼吸困难与急救药物使用(r=0.32,p<0.0001)、临床医生报告的 mMRC(r=0.33,p<0.0001)和 FEV1%预测值(r=-0.17,p<0.05)相关。E-RS 评分根据慢性支气管炎诊断(p<0.01-0.001)、吸烟状况(p<0.05-0.001)和急救药物使用(p<0.05-0.0001)区分了不同的组别。
结果表明,RS 总分是评估稳定期 COPD 呼吸症状严重程度的可靠和有效的工具。需要进一步研究其对变化的敏感性。